INT16194
From wiki-pain
|
|
|
|
|
Sentences Mentioned In
Key: | Protein | Mutation | Event | Anatomy | Negation | Speculation | Pain term | Disease term |
The present investigation examines several series of CP-47,497 analogs for their binding affinity at the cannabinoid receptor and their ability to evoke analgesia in rodents. | |||||||||||||||
| |||||||||||||||
|
This structure-activity relationship investigation was initiated to determine which effects might correspond to binding affinity for the cannabinoid receptor, as well as to explore the binding requirements of this site. | |||||||||||||||
| |||||||||||||||
|
In turn, the activated post-synaptic neuron releases endocannabinoids such as anandamide (Freund et al 2003; Navari 2003; Piomelli 2003) These endogenous CB1 ligands then diffuse back and bind to the pre-synaptic CB1 receptor (Piomelli 2003). | |||||||||||||||
| |||||||||||||||
|
AJA binds weakly to CB1 only at concentrations many fold higher than its therapeutic range, and is, therefore, completely free of psychotropic effects in both normal subjects and pain patients suggesting the involvement of a target site other than CB1. | |||||||||||||||
| |||||||||||||||
|
Most of the agonists exhibit nonselective affinity for CB1/CB2 receptors, and delta9-THC and anandamide probably act as partial agonists. | |||||||||||||||
| |||||||||||||||
|
To this date, it has been documented the presence in the CNS of specific lipids that bind naturally to the CB1/CB2 receptors. | |||||||||||||||
| |||||||||||||||
|
Anandamide (arachidonylethanolamide), isolated from porcine brain, has been shown to bind to the cannabinoid receptor and also to produce cannabimimetic activity in pharmacological assays. | |||||||||||||||
| |||||||||||||||
|
Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs. | |||||||||||||||
| |||||||||||||||
|
The cannabinoid receptor mediating this response has been characterized by its ability to bind the cannabinoid agonist [3H]CP-55,940 and to inhibit adenylyl cyclase via Gi. | |||||||||||||||
| |||||||||||||||
|
Two CB receptors have been identified in humans (CB1 and CB2) which are recognized exclusively by cannabinoids. | |||||||||||||||
| |||||||||||||||
|
Anandamide (arachidonylethanolamide) is a brain constituent which binds to the cannabinoid receptor. | |||||||||||||||
| |||||||||||||||
|
A new class of cannabinoid ligands was rationally designed from known aminoalkylindole agonists and showed good binding and functional activities at human CB1 and CB2 receptors. | |||||||||||||||
| |||||||||||||||
|
In addition, recent evidence indicates a more general role of CB1 receptors in reward-related memories, which is consistent with the proposed role of endocannabinoids in memory-related plasticity. | |||||||||||||||
| |||||||||||||||
|
Unlike NADA, OLDA was only a weak ligand for rat CB1 receptors; but like NADA, it was recognized by the anandamide membrane transporter while being a poor substrate for fatty-acid amide hydrolase. | |||||||||||||||
| |||||||||||||||
|
This compound displays nanomolar affinity (Ki = 0.56 and 3.5 nM) for both the rat brain and human CB1 recombinant receptors, respectively. | |||||||||||||||
| |||||||||||||||
|
CB1A, Ki = 298 nM), these agonists bound to CB1A (CP 55,940, WIN 55212-2 and delta 9-THC, Ki = 7.24,345 and 26.7 nM, respectively) with about 3-fold less affinity than to CB1 (CP 55,940, WIN 55212-2 and delta 9-THC, Ki = 2.26, 93 and 7.1 nM, respectively). | |||||||||||||||
| |||||||||||||||
|
CB1A, Ki = 298 nM), these agonists bound to CB1A (CP 55,940, WIN 55212-2 and delta 9-THC, Ki = 7.24,345 and 26.7 nM, respectively) with about 3-fold less affinity than to CB1 (CP 55,940, WIN 55212-2 and delta 9-THC, Ki = 2.26, 93 and 7.1 nM, respectively). | |||||||||||||||
| |||||||||||||||
|
In turn, the activated post-synaptic neuron releases endocannabinoids such as anandamide (Freund et al 2003; Navari 2003; Piomelli 2003) These endogenous CB1 ligands then diffuse back and bind to the pre-synaptic CB1 receptor (Piomelli 2003). | |||||||||||||||
| |||||||||||||||
|
We observed that LASSBio-881 (3c) was able to bind to CB1 receptors (71% at 100microM) and also to inhibit T-cell proliferation (66% at 10microM) probably by binding to CB2 receptors, in a non-proapoptotic manner, different from anandamide (1). | |||||||||||||||
| |||||||||||||||
|
In direct binding assays on isolated membranes the agonist [3H]CP 55,940 bound in a saturable and highly specific manner to both cannabinoid receptor isoforms. | |||||||||||||||
| |||||||||||||||
|
General Comments
This test has worked.